The management of bronchiectasis is finally advancing and patients have new options in terms of diagnostics, antibiotic therapy and physiotherapy. The principles of management have not changed, but with some simple interventions patients can experience improved quality of life and health outcomes. many treatments developed for cystic fibrosis are now being applied to the management of bronchiectasis due to other causes.
Introduction
For many healthcare professionals, the term 'bronchiectasis' conjures up a bygone era of cold damp houses and coughing children. Today there is a revived interest in this condition among respiratory physicians and after many stagnant years we are able to offer something new.
The management of cystic fibrosis has rapidly improved over the past 20 years with vastly improved life expectancies.
Research has flourished, and many treatments developed for the management of cystic fibrosis-related bronchiectasis are already being used in non-cystic fibrosis bronchiectasis sufferers in the clinical setting. Compared to other respiratory disorders such as asthma, evidence for the safety and efficacy of treatments used in bronchiectasis is scarce.
What do general practitioners want to know?
There are a number of commonly asked questions regarding bronchiectasis in general practice.
What monitoring is appropriate and when?
The advent of high resolution CT scans means there is a new gold standard for diagnosis. 1 We are able to assess the anatomy and severity of patients with known disease more accurately as well as diagnosing new patients. High resolution CT chest scanning should be performed at diagnosis and as determined by clinical progress. Chest X-rays are most useful in evaluating complications such as pneumonia.
Functional monitoring with spirometry (and lung volumes where available) is very useful and should be performed both during exacerbations and in stable periods. The frequency of testing will depend on the deterioration and exacerbation rate for the individual patient.
When is the best time to perform sputum cultures?
Sputum cultures should be done when the patient is stable and, ideally, not taking antibiotics. This information can then be used to guide the management of their next exacerbation.
Patients on long-term macrolide antibiotics can still be managed along the same lines, as these drugs (in the low doses used) have little effect on actual pathogens isolated and on antibiotic susceptibility profiles.
If no sputum culture is available for a particular patient, collect a sample then treat for the more common pathogens, for example 
Does pseudomonas colonisation matter?
We know a lot more about this pathogen than we used to.
We are now aware that it forms three-dimensional structures, 
Should my patient be on long-term antibiotics?
The cautious answer to this question is, 'We don't know ' 
Should my patient be on inhaled corticosteroids?
Bronchiectasis is an inflammatory condition in which the ongoing damage of the airways is due to the inflammatory response to pathogens. Inhaled corticosteroids reduce this inflammatory damage. Several randomised controlled trials have shown a benefit of inhaled corticosteroids in patients with bronchiectasis, with the main improvements being reduced sputum production and exacerbations. 4 Are there any new medications to assist sputum clearance?
Drugs to assist sputum clearance are seeing a revival with research into using two osmotic agents -nebulised hypertonic saline and inhaled mannitol. Both of these agents have been shown to assist sputum clearance predominantly by increasing hydration of the sputum and improving the viscosity. Hypertonic saline has been shown to reduce exacerbation rates in a large cystic fibrosis trial. 5 In non-randomised studies, mannitol improved airway clearance and quality of life in patients with non-cystic fibrosis bronchiectasis. A large randomised controlled trial has just been completed. Neither treatment is available commercially at the time of writing but hypertonic saline is available through public hospital outpatient clinics, and mannitol should be available as a metered-dose inhaler over the next few years.
Is pulmonary rehabilitation of benefit?
All patients with chronic lung disease and dyspnoea warrant some form of pulmonary rehabilitation to prevent the inevitable deconditioning that occurs and exacerbates the dyspnoea. There has not been much research for patients with bronchiectasis, but one study has clearly demonstrated benefit. 6 What long-term sequelae should I be aware of?
The important long-term sequelae in bronchiectasis are respiratory failure, cor pulmonale, nocturnal hypoventilation, poor nutrition, osteoporosis and haemoptysis.
Respiratory failure can be hypoxic or hypercapnic or both.
Hypoxic patients benefit from home oxygen and this can be 
Vaccinations
Patients with bronchiectasis should be considered 'at risk' for serious sequelae from pneumococccal and influenzal illness. There is an increased risk of cardiac arrhythmia and sudden death during general anaesthesia for central venous catheter replacement. This has been observed in patients with cardiac hypertrophy. Acute respiratory failure has also occurred in one
New drugs
Some of the views expressed in the following notes on newly approved products should be regarded as tentative, as there may be limited published data and little experience in Australia of their safety or efficacy. However, the Editorial Executive Committee believes that comments made in good faith at an early stage may still be of value. As a result of fuller experience, initial comments may need to be modified. The Committee is prepared to do this. Before new drugs are prescribed, the Committee believes it is important that full information is obtained either from the manufacturer's approved product information, a drug information centre or some other appropriate source.
